Notch signals driving T‑cell lymphoma and new treatment options
Notch ligands as oncogenic drivers and therapeutic targets in T-cell lymphomas
['FUNDING_R01'] · UNIVERSITY OF MICHIGAN AT ANN ARBOR · NIH-11240310
This research looks at whether blocking Notch signals from nearby support cells can stop growth of peripheral T‑cell lymphoma and point to new treatments for people with relapsed or resistant disease.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF MICHIGAN AT ANN ARBOR (nih funded) |
| Locations | 1 site (ANN ARBOR, UNITED STATES) |
| Trial ID | NIH-11240310 on ClinicalTrials.gov |
What this research studies
Researchers are using patient tumor samples and genetically engineered mouse models to study peripheral T‑cell lymphoma (PTCL) from the patient's perspective. They focus on Notch signals coming from stromal support cells, especially fibroblastic reticular cells, and use techniques like ATAC‑seq and gene expression profiling to see how those signals change tumor behavior. The team will test whether interrupting Notch ligands or stromal support reduces lymphoma growth in lab models and mice. The ultimate aim is to find drug‑targetable vulnerabilities that could lead to new therapies for people with aggressive or treatment‑resistant PTCL.
Who could benefit from this research
Good fit: Ideal candidates are people diagnosed with peripheral T‑cell lymphoma, especially those with relapsed or refractory disease who may benefit from new targeted approaches.
Not a fit: People without PTCL, or patients whose disease is driven by different pathways, are unlikely to receive direct benefit from this research in the near term.
Why it matters
Potential benefit: If successful, this work could identify new drug targets that lead to therapies slowing or stopping PTCL growth and improving survival.
How similar studies have performed: Notch‑targeting approaches have shown activity in some other cancers but are not yet established for PTCL, so this application is exploratory and not yet proven.
Where this research is happening
ANN ARBOR, UNITED STATES
- UNIVERSITY OF MICHIGAN AT ANN ARBOR — ANN ARBOR, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: WILCOX, RYAN A — UNIVERSITY OF MICHIGAN AT ANN ARBOR
- Study coordinator: WILCOX, RYAN A
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancers